An observational study in Patency of the Ductus Arteriosus Acetaminophen Extreme Prematurity, sponsored by Institut National de la Santé Et de la Recherche Médicale, France. Recruiting at 8 sites in France. Open to participants aged 23 Months to 27 Months. Per ClinicalTrials.gov, last updated 2026-04-16.
Sponsored by Institut National de la Santé Et de la Recherche Médicale, France · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 205 studies in Premature Birth with a site in France — 40 open to participants now, 46 under way, 2 of them phase 3. Premature Birth · France.
Among the 205 studies in Premature Birth with a site in France, this one is the 23rd largest by planned enrollment of the 99 observational ones that give a count, is one of 11 that started in 2023, is one of 99 observational ones, reaches primary completion later than 21 of the 45 other live ones, and was the 174th registered.
2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.
Browse Premature Birth studies →40 of the 205 studies in Premature Birth with a site in France are open now. Recruiting first, the newest first:
Institut National de la Santé Et de la Recherche Médicale, France · Sites in France
Ages up to 5 mo · Healthy volunteers
University Hospital, Strasbourg, France · Sites in France
Ages 0 mo–18 mo
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 6 yrs–78 mo
Bioprojet · Sites in France
Ages 18–50 · Men only
Hospices Civils de Lyon · Sites in France
Ages up to 32 wk
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.
This study: 23 Months to 27 Months · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
205 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 12 · Phase 4 10
First in 1997; this study’s year is marked. 11 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 120 across 809 observational studies indexed under Premature Birth.
Median enrollment 98 across the 104 interventional studies, 130 across the 99 observational. Of the 139 that completed or were terminated, 2 (1%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 205 have an industry lead sponsor. The 10 most frequent:
Institut National de la Santé Et de la Recherche Médicale, France is the lead sponsor of 378 studies on the registry; 81 are open to participants now.
Institut National de la Santé Et de la Recherche Médicale, France has 5 studies filed under Premature Birth — fewer than ten, so there is no comparison to draw.
16 of the studies in Premature Birth with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03976063Phase 3Assistance Publique - Hôpitaux de ParisTocolysis in the Management of Preterm Premature Rupture of Membranes Before 34 Weeks of Gestation | 2026-11 |
| NCT04372953Murdoch Childrens Research InstitutePositive End-Expiratory Pressure (PEEP) Levels During Resuscitation of Preterm Infants at Birth (The POLAR Trial). | 2026-11-30 |
| NCT06064825Institut National de la Santé Et de la Recherche Médicale, FranceLong Term Follow-up of the TREOCAPA Study (TREOCAPA-LT) | 2026-12 |
| NCT07047404BioprojetProof of Concept Study on BP1.4979 Effect on Primary Premature Ejaculation | 2026-12 |
| NCT07169110University Hospital, ToulouseStudy of the Interprofessional Reproducibility of a Clinical Observation Scale for the Development of Very Premature Infants | 2026-12-30 |
Add all 16 to your calendar (.ics) → With an account.
Among the 205 studies in Premature Birth with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The ductus arteriosus (DA) is a large channel connecting the main pulmonary trunk with the descending aorta. In extremely preterm infants, the DA frequently fails to close and this results in a condition called patent ductus arteriosus (PDA). In these patients, PDA has been associated with increased mortality and morbidity in the neonatal period, and neonatal morbidities may in turn be associated with later deficits in cognitive functioning. PDA treatment with COX inhibitors, as ibuprofen or indomethacin, aiming at closing the PDA have been associated with numerous adverse effects and failed to demonstrate significant clinical benefits. Early treatment of PDA with paracetamol (acetaminophen ) has been proposed as an alternative to COX inhibitors. The ongoing pan-European TREOCAPA phase III study (NCT04459117) is a multicentre, double-blind, randomised, placebo-controlled superiority trial that assesses prophylactic use of paracetamol to improve survival without severe neonatal morbidity until discharge from hospital in infants of 23-28 weeks of gestational age. As long-term follow-up was not planned by the TREOCAPA protocol, TREOCAPA-LT study will use an existing European research infrastructure, the RECAP Preterm platform (https://recap-preterm.eu/), to follow-up the patients enrolled in the TREOCAPA trial using a parent-report questionnaire at 2 years of corrected age.
The TREOCAPA-LT primary hypothesis is that there will be improved cognitive outcome at 2 years of corrected age in children born at less than 29 weeks of gestational age who were treated with paracetamol during the first 5 days of life in the TREOCAPA phase III trial.
The ductus arteriosus (DA) is a large channel found normally in all mammalian foetuses, connecting the main pulmonary trunk with the left-sided descending aorta. During fetal life, it diverts most of the combined ventricular output away from the lungs toward the placenta. In full-term newborns, the DA is functionally open in all newborns and its constriction and closure, within 24 to 48 hours after delivery, are part of the normal process of postnatal adaptation. In extremely preterm infants, ie, those born before 29 weeks of gestation, the DA frequently fails to close and this results in a condition called patent ductus arteriosus (PDA). In these patients, PDA has been associated with increased mortality and morbidity in the neonatal period, and neonatal morbidities may in turn be associated with later deficits in cognitive functioning. Inhibition of prostaglandin synthesis, through inhibition of the cyclo-oxygenase (COX) enzymes, results in ductal constriction. However, treatments with COX inhibitors, as ibuprofen or indomethacin, aiming at closing the PDA have been associated with numerous adverse effects and failed to demonstrate significant clinical benefits. Prophylactic use of indomethacin or ibuprofen has been shown to reduce subsequent development of PDA but not to reduce mortality or morbidity. Further, investigations of early cardiac ultrasound-targeted treatment of a large PDA using indomethacin and ibuprofen do not show efficacy on primary outcomes of neonatal death or morbidity. Although this evidence base shows that prophylactic treatment by indomethacin or ibuprofen cannot be recommended, evidence from observational studies suggests that early (during the first 3 days of life) conservative treatment should not be recommended either. Two observational studies indicated that ignoring a PDA during the first days of life is associated with increase in mortality or morbidity. Our interpretation of these results is that screening echocardiography of large ductus arteriosus and early targeted treatment using echocardiography reduce pulmonary haemorrhage, but that the use of drugs with severe adverse effects may cancel expected beneficial effects on the occurrence of death or morbidity.
The use of a medication with an effect on PDA and that has fewer adverse effects is therefore desirable. Early treatment of PDA with paracetamol (acetaminophen) has been proposed as an alternative to COX inhibitors. According to a recent meta-analysis, use of paracetamol has a comparable effectiveness to close a PDA, and fewer harmful effects. However, only few extremely preterm infants were included in this meta-analysis. Therefore, efficacy and safety of paracetamol for PDA treatment in this population required further studies.
The ongoing pan-European TREOCAPA phase III study (NCT04459117) is a multicentre, double-blind, randomised, placebo-controlled superiority trial that assesses prophylactic use of paracetamol to improve survival without severe neonatal morbidity until discharge from hospital in infants of 23-28 weeks of gestational age.12 The trial has been powered to identify an absolute difference of 10% in the primary outcome, survival without severe neonatal morbidity (defined as any of: bronchopulmonary dysplasia grade 3 according to National Institute of Health criteria, necrotising enterocolitis stage 2 or 3 using Bell's criteria, intraventricular haemorrhage grade III or IV using the classification of Papile et al, or any evidence of cystic periventricular leukomalacia), corresponding to an increase from 50% to 60% in the rate between groups at hospital discharge. It aims to recruit 398 infants born at 27-28 weeks of gestation, and 396 infants born at 23-26 weeks of gestation. The first patients were recruited in October 2020 and the recruitment period is anticipated to last until April 2024 at the latest.
The TREOCAPA phase III trial is ambitious and innovative in its scope, including more than 40 hospitals in 16 countries. However, long-term follow-up was not included in the TREOCAPA protocol. The follow-up of infants enrolled in clinical trials enables to measure the long-term effectiveness and safety of interventions performed in the neonatal period. In particular for exposition to paracetamol in the neonatal period, data from randomized studies are very limited, while long-term adverse effects of paracetamol, including notably behavioral problems, have been raised. There is hence a need to understand longer term outcomes for the infants enrolled in this study, as these longer-term endpoints correspond to important patient-valued outcomes and are critical to determining the comparative effectiveness of interventions. The working hypothesis, if the intervention has a positive impact on short-term endpoints, is that longer term outcomes will be better in the intervention group, reflecting reduced morbidity at discharge home from the neonatal hospitalisation.
As long-term follow-up was not planned by the TREOCAPA phase III protocol, TREOCAPA-LT study will use an existing European research infrastructure, the RECAP Preterm platform to follow-up patients enrolled in the TREOCAPA cohort at 2 years of corrected age. This platform federates 23 European longitudinal observational cohorts of children born very preterm. The platform includes expertise, tools and infrastructure to follow patients enrolled in trials. By integrating trial follow-up in this platform, it is also possible to compare patients enrolled in the TREOCAPA trial with those from population-based samples, allowing assessment of transportability of trial results.
Follow-up at 2 years of age is recommended as the focus for the first phase of long-term outcome monitoring and has become the de facto age which is used in many published and ongoing clinical trials. Furthermore, many hospital services provide follow-up for their patients until at least 2 years of age, and research contact with the families at this point provides an opportunity to maintain contact and demonstrate to patients the ongoing importance of their involvement in the study.
The TREOCAPA-LT primary hypothesis is that there will be improved cognitive outcome at 2 years of corrected age in children born at less than 29 weeks of gestational age who were treated with paracetamol during the first 5 days of life in the TREOCAPA trial.
Secondary hypotheses are that, among children treated with paracetamol/acetaminophen during the first 5 days of life:
Secondary hypotheses also relate to the use of the RECAP Preterm platform of observational VPT cohorts in this study. These are that:
The study population for the follow-up study of the TREOCAPA trial consists of all children included in phase III of the trial from centres participating in the follow-up study. The parents of children who survived to two years corrected age and meet the criteria for inclusion will be offered the opportunity to complete the questionnaire.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
This group of patients received the investigational product in their first 5 days of life during the Treocapa trial
Other: 2 year follow-up of neurodevelopment using a parental questionnaire
This group of patients received the placebo in their first 5 days of life during the Treocapa trial
Other: 2 year follow-up of neurodevelopment using a parental questionnaire
A parental questionnaire, using the PARCA-R instrument, is given to measure cognitive outcome at 2 years of corrected age for children included in the Treocapa Trial
Non-verbal cognition at 2 years corrected age
Non-verbal cognitive (NVC) scale score from the Parent Report of Children's Abilities-Revised (PARCA-R) questionnaire, administered using an on-line parental questionnaire. The score is standardised such that it has a mean of 100 and a standard deviation of 15. Lower scores mean worse outcomes.
Time frame: from 23,5 to 27,5 months of corrected age
Survival without moderate or severe cognitive impairment
Definied as survival to 2 years corrected age with a PARCA-R NVC scale score less than 2 standard deviations below the mean.
Time frame: from 23,5 to 27,5 months of corrected age
Survival without moderate or severe neurodevelopmental impairment based on the presence of at least one of the impairments in the description :
1. the PARCA-R NVC \< 2 standard deviations below the mean; 2. moderate to severe motor impairment, as measured using parent reported questions, defined as a child unable to: walk without assistance or aids or sit or hold their head up without support19; 3. unilateral or bilateral deafness or blindness as measured by parent reported questions: if the child is deaf or has functional hearing loss requiring correction with aids but still has difficulty hearing, or if the child is blind or able to see light only19.
Time frame: from 23,5 to 27,5 months of corrected age
Health service use and costs
Reported by parents in the questionnaire, using questions on visits to health service providers and other costs associated with care of the children that have been used in previous European studies
Time frame: from 23,5 to 27,5 months of corrected age
Comparisons of the results with observational cohorts of very preterm infants for maternal sociodemographic characteristics
Descriptive statistics on maternal sociodemographic characteristics
Time frame: This analysis will be carried during the 12 months after the end of data collection.
Comparisons of the results with observational cohorts of very preterm infants for gestational age
Descriptive statistics on gestational age
Time frame: This analysis will be carried during the 12 months after the end of data collection.
Comparisons of the results with observational cohorts of very preterm infants on sex
Descriptive statistics on sex
Time frame: This analysis will be carried during the 12 months after the end of data collection.
Comparisons of the results with observational cohorts of very preterm infants for complication of pregnancy
Descriptive statistics on complications of pregnancy
Time frame: This analysis will be carried during the 12 months after the end of data collection.
Comparisons of the results with observational cohorts of very preterm infants for birth
Descriptive statistics on complication of birth
Time frame: This analysis will be carried during the 12 months after the end of data collection.
Comparisons of the results with observational cohorts of very preterm infants for neonatal morbidities
Descriptive statistics on neonatal morbidities
Time frame: This analysis will be carried during the 12 months after the end of data collection.
Comparisons of the results with observational cohorts of very preterm infants for mortality
Descriptive statistics on mortality
Time frame: This analysis will be carried during the 12 months after the end of data collection.
Comparisons of the results with observational cohorts of very preterm infants for neurodevelopment
Descriptive statistics on two-year neurodevelopment
Time frame: This analysis will be carried during the 12 months after the end of data collection.
Plan to share: No
Started Dec 2023 (actual). Primary completion is estimated for Dec 2026, 36 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institut National de la Santé Et de la Recherche Médicale, France →